The emergence of COVID-19 variants such as delta and omicron have sent scientists scrambling to determine whether existing vaccinations and boosters are still effective against new strains of SARS-Cov-2.
Swedish researchers are gearing up to seek permission from Bangladeshi authorities to hold clinical trials of a nasal COVID-19 vaccine in the country, reported the Dhaka Tribune.
Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus.